Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide in Pediatric IBS-C
NCT02559817Phase 2Terminated
- Sponsor
- Forest Laboratories
- Start
- Nov 2015
- Primary completion
- Aug 2019
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of linaclotide in irritable bowel syndrome with constipation (IBS-C) (5 arms), sponsored by Forest Laboratories. Primary endpoint: Change From Baseline in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate. Started Nov 2015; status: terminated.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome with constipation (IBS-C)
Beyond the preview
Go deeper on NCT02559817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559817.